CB-011 - (CaMMouflage)

June 11, 2026: Caribou Biosciences, Inc. (NASDAQ: CRBU) reported longer follow-up from the ongoing CaMMouflage Phase 1 trial of CB-011, an off-the-shelf (allogeneic) BCMA-targeted CAR-T for relapsed/refractory multiple myeloma, and announced an EHA 2026 oral presentation (June 14, 2026, 11:00am CEST; abstract S201).

CaMMouflage Phase 1 (dose escalation; BCMA-naïve RDE cohort): As of the May 26, 2026 efficacy cutoff, 48 patients had been treated overall. The recommended dose for expansion (RDE) was 450 million CB-011 CAR-T cells after lymphodepletion with cyclophosphamide 500 mg/m² and fludarabine 30 mg/m² daily for three days. In 12 BCMA-naïve patients treated at the RDE (median follow-up 17.7 months), efficacy included 92% ORR, 83% ≥CR, 91% MRD negativity (10/11 evaluable), and 50% in ≥CR at 15 months.

Safety (Apr 20, 2026 cutoff): No GvHD or certain other specified toxicities in any treated patient (N=48). With the selected LD regimen (N=35), there was one CB-011-related death from immune effector cell-associated hematotoxicity. In the 12-patient RDE cohort, ≥Grade 3 ICANS was 0% and ≥Grade 3 CRS was 8%.

Case study (BCMA-exposed): A 71-year-old previously treated with ciltacabtagene autoleucel achieved a CR by day 28 after a single 450M-cell CB-011 dose, ongoing as of May 26, 2026.

Upcoming: Initial dose expansion data in BCMA-naïve and BCMA-exposed patients are expected in H2 2026.